Genenta Science S.P.A. ADR (GNTA)

$2.04 +0.08 (4.08%)
Market Cap 49.78M
Revenue (ttm) 0.00
Net Income (ttm) -7.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 740,900
Avg Vol 1,731,740
Day's Range N/A - N/A
Shares Out 23.59M
Stochastic %K 73%
Beta 0.90
Analysts Strong Buy
Price Target $7.00

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 39 02 26434681
Address:
Via Olgettina No. 58, Milan, Italy
mcewing
mcewing Jun. 5 at 8:23 PM
$GNTA positive on a blood bath day.
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Jun. 5 at 8:07 PM
$RMSG $HUBC $GNTA $SDOT RMSG was the perfect end to a fun week for the bulls. Feeling thankful. Have a great weekend everyone!
0 · Reply
creyl
creyl Jun. 5 at 6:20 PM
$GNTA short borrow fee rate still 763.25
0 · Reply
creyl
creyl Jun. 5 at 2:24 PM
$GNTA super
0 · Reply
creyl
creyl Jun. 5 at 2:23 PM
$GNTA super
0 · Reply
goudaconjo
goudaconjo Jun. 5 at 2:20 PM
$GNTA we go
0 · Reply
creyl
creyl Jun. 5 at 2:17 PM
$STI over and out...thx all...all in @ $GNTA
0 · Reply
Fakhrul123
Fakhrul123 Jun. 5 at 8:50 AM
$GNTA $5 please
0 · Reply
Rwhitacre91
Rwhitacre91 Jun. 4 at 6:46 PM
$GNTA
1 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:35 PM
$GNTA something is coming here
0 · Reply
Latest News on GNTA
Genenta signs Definitive Agreements with Sophia High Tech

Apr 23, 2026, 7:00 AM EDT - 6 weeks ago

Genenta signs Definitive Agreements with Sophia High Tech

Genenta Science enters binding offer to fund Sophia High Tech

2026-03-27T09:05:10.000Z - 2 months ago

Genenta Science enters binding offer to fund Sophia High Tech

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

Mar 27, 2026, 5:00 AM EDT - 2 months ago

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Mar 24, 2026, 3:27 AM EDT - 2 months ago

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Mar 13, 2026, 5:00 AM EDT - 3 months ago

Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Feb 27, 2026, 4:00 AM EST - 3 months ago

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Genenta Science to change name to Saentra Forge, seeks controlling stake in ATC

2026-01-27T10:25:23.000Z - 4 months ago

Genenta Science to change name to Saentra Forge, seeks controlling stake in ATC

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Jan 27, 2026, 3:00 AM EST - 4 months ago

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Genenta Science Provides Update on CEO Ownership

Dec 19, 2025, 2:30 AM EST - 6 months ago

Genenta Science Provides Update on CEO Ownership

Genenta Science provides update from TEM-GBM study

2025-11-24T10:10:13.000Z - 6 months ago

Genenta Science provides update from TEM-GBM study

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Nov 24, 2025, 4:00 AM EST - 6 months ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Oct 26, 2025, 8:30 PM EDT - 7 months ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Why Is Genenta Science Stock (GNTA) Up 275% Today?

2025-10-24T12:36:37.000Z - 8 months ago

Why Is Genenta Science Stock (GNTA) Up 275% Today?

Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology

2025-10-24T09:10:19.000Z - 8 months ago

Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Oct 24, 2025, 4:00 AM EDT - 8 months ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Science announces follow-up observations in glioblastoma study

2025-07-01T09:25:53.000Z - 1 year ago

Genenta Science announces follow-up observations in glioblastoma study

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Jul 1, 2025, 5:00 AM EDT - 1 year ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 1 year ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta Science, Anemocyte announce collaboration

2025-05-07T11:43:50.000Z - 1 year ago

Genenta Science, Anemocyte announce collaboration

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025, 7:00 AM EDT - 1 year ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Apr 15, 2025, 5:00 AM EDT - 1 year ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Science announces EUR 20M financing to expand pipeline

2025-03-19T13:37:19.000Z - 1 year ago

Genenta Science announces EUR 20M financing to expand pipeline

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Mar 19, 2025, 9:28 AM EDT - 1 year ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 28, 2025, 8:01 AM EST - 1 year ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Science announces amendment to pact with AGC Biologics

2025-01-09T11:51:43.000Z - 1 year ago

Genenta Science announces amendment to pact with AGC Biologics

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 9, 2025, 6:00 AM EST - 1 year ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 8, 2025, 3:17 PM EST - 1 year ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Science SPA (ADR) trading resumes

2024-11-29T14:45:23.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

Genenta Science SPA (ADR) trading halted, volatility trading pause

2024-11-29T14:35:20.000Z - 1 year ago

Genenta Science SPA (ADR) trading halted, volatility trading pause

Genenta Science CEO to present at U.S. Senate meeting

2024-10-23T11:20:34.000Z - 1 year ago

Genenta Science CEO to present at U.S. Senate meeting

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Genenta Science SPA (ADR) trading resumes

2024-10-21T14:17:06.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

Genenta Science SPA (ADR) trading resumes

2024-10-10T13:55:20.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

Genenta Science SPA (ADR) trading halted, volatility trading pause

2024-10-10T13:50:09.000Z - 1 year ago

Genenta Science SPA (ADR) trading halted, volatility trading pause

Genenta Science secures approval for trial for metastatic Renal Cell Cancer

2024-10-02T10:42:04.000Z - 1 year ago

Genenta Science secures approval for trial for metastatic Renal Cell Cancer

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 2 years ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Science doses first three TEM-GBM patients in Cohort 8

2024-02-08T10:05:35.000Z - 2 years ago

Genenta Science doses first three TEM-GBM patients in Cohort 8

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 8, 2024, 5:00 AM EST - 2 years ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023, 3:00 AM EDT - 3 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Genenta Science SpA(ADR) trading resumes

2023-07-13T16:33:14.000Z - 3 years ago

Genenta Science SpA(ADR) trading resumes

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023, 7:00 AM EDT - 3 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 2, 2023, 6:45 AM EST - 3 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 4 years ago

Genenta to Present at Upcoming Investor Conferences

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022, 6:00 AM EDT - 4 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022, 7:30 AM EDT - 4 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 9, 2022, 7:30 AM EDT - 4 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 4 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 4, 2022, 7:30 AM EDT - 4 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 2, 2022, 4:30 PM EDT - 4 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 4 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022, 7:30 AM EDT - 4 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

mcewing
mcewing Jun. 5 at 8:23 PM
$GNTA positive on a blood bath day.
0 · Reply
StockSenseiTrendTraders
StockSenseiTrendTraders Jun. 5 at 8:07 PM
$RMSG $HUBC $GNTA $SDOT RMSG was the perfect end to a fun week for the bulls. Feeling thankful. Have a great weekend everyone!
0 · Reply
creyl
creyl Jun. 5 at 6:20 PM
$GNTA short borrow fee rate still 763.25
0 · Reply
creyl
creyl Jun. 5 at 2:24 PM
$GNTA super
0 · Reply
creyl
creyl Jun. 5 at 2:23 PM
$GNTA super
0 · Reply
goudaconjo
goudaconjo Jun. 5 at 2:20 PM
$GNTA we go
0 · Reply
creyl
creyl Jun. 5 at 2:17 PM
$STI over and out...thx all...all in @ $GNTA
0 · Reply
Fakhrul123
Fakhrul123 Jun. 5 at 8:50 AM
$GNTA $5 please
0 · Reply
Rwhitacre91
Rwhitacre91 Jun. 4 at 6:46 PM
$GNTA
1 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:35 PM
$GNTA something is coming here
0 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:34 PM
$SOAR get $GNTA
0 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:33 PM
$HUBC buy $GNTA instead
0 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:33 PM
$LASE get $GNTA instead
0 · Reply
goudaconjo
goudaconjo Jun. 4 at 2:32 PM
$STI buy $GNTA
0 · Reply
mcewing
mcewing Jun. 4 at 1:54 PM
$GNTA nice rebound. Something is up with this company.
0 · Reply
creyl
creyl Jun. 4 at 9:35 AM
$GNTA could squeeze hard
1 · Reply
HarmonyPioneer67
HarmonyPioneer67 Jun. 4 at 8:34 AM
$GNTA
1 · Reply
creyl
creyl Jun. 3 at 5:57 PM
$GNTA strong 💪
0 · Reply
goudaconjo
goudaconjo Jun. 3 at 3:15 PM
$GNTA
0 · Reply
creyl
creyl Jun. 3 at 3:01 PM
$GNTA
0 · Reply
goudaconjo
goudaconjo Jun. 3 at 2:59 PM
$GNTA testing $3 today
0 · Reply
creyl
creyl Jun. 3 at 2:58 PM
$GNTA let's go
0 · Reply